Benchling Launches AI-Powered Deep Research Agent to Accelerate Biotech R&D

San Francisco, CA – Benchling, the R&D Cloud platform for the biotechnology industry, has announced the general availability of its new AI-powered Deep Research Agent. This significant product launch, designed to transform how scientists access and leverage experimental data, was highlighted by Lux Capital co-founder Josh Wolfe, who lauded the company and its CEO.

The Deep Research Agent aims to provide scientists with an intelligent search engine that utilizes experimental data and scientific literature to answer complex research questions, streamlining lab work and accelerating discovery. Sajith Wickramasekara, co-founder and CEO of Benchling, expressed excitement about the new offering on social media, stating, "Excited that Benchling’s Deep Research Agent is now available to all customers."

This product release follows a period of significant growth and strategic partnerships for Benchling. In the first half of its fiscal year, the company surpassed 1,000 customers and achieved a 90% year-over-year increase in subscription revenue. These milestones underscore Benchling's expanding footprint in the life sciences sector.

Earlier this year, in June 2025, Benchling also forged a new collaboration with pharmaceutical giant Merck. This partnership focuses on implementing a software framework to integrate Merck's pre-clinical and clinical bioanalytical workflows onto a unified platform, enhancing efficiency and compliance in vaccine development. According to Sajith Wickramasekara, this collaboration "demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis."

Lux Capital, a long-term investor in Benchling since its seed round in 2015, has participated in every subsequent funding round, including the $100 million Series F in November 2021, which valued the company at $6.1 billion. Josh Wolfe's recent tweet, "> Lux family co @benchling founder CEO🔥", reflects the venture capital firm's continued enthusiasm and confidence in Benchling's innovation and market leadership. Benchling, founded in 2012 by Wickramasekara and Ashu Singhal, continues to solidify its position as a critical technology provider for modern biotechnology research and development.